This document details the administered, departmental and total funding amounts for capped costings included in Appendix C, Table C-1 of the 2019 Post-election report.

This document details the administered, departmental and total funding amounts for capped costings included in Appendix C, Table C-1 of the 2019 Post-election report.

This document details the administered, departmental and total funding amounts for capped costings included in Appendix C, Table C-1 of the 2019 Post-election report.

This document details the administered, departmental and total funding amounts for capped costings included in Appendix C, Table C-1 of the 2019 Post-election report.

This document details the administered, departmental and total funding amounts for capped costings included in Appendix C, Table C-1 of the 2019 Post-election report.

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

This proposal would establish a new agency, the National Preventative Health Commission (the
Commission). The Commission would play a role in preventative and public health policy oversight,
provide advice to the Commonwealth Government, and undertake health promotion, including
through offering grants for health promotion initiatives.

The funding for the Commission would be equal to the sum of funding for the Victorian Health
Promotion Foundation (VicHealth) and the former Australian National Preventive Health Agency.